Abstract 1328P
Background
TKIs targeting the EGFR revolutionized care of patients (pts) with non-small cell lung cancer (NSCLC) harboring EGFR mutations. Resistance to 1st/2nd-generation EGFR TKIs inevitably develops, with clone(s) harboring T790M EGFR mutations emerging in 50–70% of cases. 3rd-generation EGFR TKIs active against T790M and common EGFR-activating mutations are in development; only osimertinib and aumolertinib have regulatory approvals.
Methods
We have described a novel approach for assessing treatment efficacy using measurements of tumor burden to estimate rates of growth and regression of tumors designated g and d , respectively. Data from thousands of pts with diverse tumors have shown g is inversely correlated with OS. We analyzed data from the randomized phase III AENEAS study comparing aumolertinib with gefitinib.
Results
94% of the data could be analyzed; notably more pts than included for the primary PFS endpoint. Tumor growth reflected in a detectable g was found in 89% of both arms, including many not scored as progression. Superiority of aumolertinib was evident in statistically slower g values [and longer tumor doubling times, TDT] for aumolertinib [ g = 0.0006/day (0.0005-0.0011); TDT 1155 days] than gefitinib, [ g = 0.0012/day (0.0007-0.0020); TDT, 578 days], p<0.0001. Aumolertinib was superior in slowing g in tumors with Ex19del alterations compared to L858R mutations [p=0.0018], and superior to gefitinib in slowing g in tumors with Ex19del alterations [p<0.0001] just missing significance for L858R mutations [p=0.0687] – possibly due to smaller number of pts. Aumolertinib slowed g in non-smokers compared to smokers [p=0.0066] and superior to gefitinib in slowing g in non-smokers [p<0.0001]. Finally, g values with aumolertinib were comparable to published osimertinib values. Table: 1328P
Median rate of tumor growth (g) by line and type of therapy
Line of therapy | Type of therapy | N | Median g /day | Tumor Doubling Time |
Data from USFDA Analysis [ Gong, ASCO 2020 ] | ||||
Front | Mono 1stGen EGFRi* | 237 | 0.0012/day | 578 days |
Front | Osimertinib | 243 | 0.0007/day | 990 days |
Data from analysis of AENEAS study | ||||
Front | Gefitinib | 215 | 0.0012/day | 578 days |
Front | Aumolertinib | 214 | 0.0006/day | 1155 days |
*1st generation EGFR inhibitors, gefitinib or erlotinib
Conclusions
Like osimertinib, aumolertinib is a highly effective third-generation EGFR-TKI.
Clinical trial identification
NCT03849768.
Editorial acknowledgement
Legal entity responsible for the study
Hansoh Pharmaceutical Group Co, Ltd.
Funding
Has not received any funding.
Disclosure
S. Lu: Financial Interests, Institutional, Invited Speaker: Hansoh, AstraZeneca, Roche, Hengrui; Financial Interests, Institutional, Advisory Board: AstraZeneca, Pfizer, Boehringer Ingelheim, Hutchison MediPharma, ZaiLab, GenomiCare, Yuhan Corporation, Menarini, InventisBio Co. Ltd, Roche, Simcere Zaiming Pharmaceutical Co., Ltd.; Financial Interests, Research Grant: AstraZeneca, Hutchison, BMS, Heng Rui, Roche, Hansoh, BeiGene, Lilly Suzhou Pharmaceutical Co. Ltd; Financial Interests, Coordinating PI: FibroGen. H. Wei: Financial Interests, Institutional, Full or part-time Employment, Medical staff: Hansoh Pharmaceutical Group Co, Ltd.. S.E. Bates: Financial Interests, Personal, Advisory Role: Pegascy, ElmediX, Servier, OnKure, Ipsen; Financial Interests, Institutional, Licensing Fees or royalty for IP: Deacetylase Inhibitor Therapy, Depsipeptide for Therapy of Kidney Cancer; Financial Interests, Personal, Research Funding: Pfizer; Financial Interests, Institutional, Research Funding: Merck, Amgen, RenovoRx, Ipsen, Pfizer. L. Schwartz: Financial Interests, Personal, Advisory Role: Novartis, Regeneron, Bristol Myers Squibb/Celgene; Financial Interests, Personal, Royalties: Varian Medical Systems; Financial Interests, Institutional, Research Funding: Merck Sharp & Dohme, Boehringer Ingelheim. A.T. Fojo: Financial Interests, Personal, Financially compensated role: Merck; Financial Interests, Personal, Advisory Role: Akita Biomedical; Financial Interests, Institutional, Research Funding: Ipsen, Pfizer, Merck. All other authors have declared no conflicts of interest.
Resources from the same session
1353P - Effect of TP53 co-mutation in non-small cell lung cancer (NSCLC) with driver mutations
Presenter: Jamie Feng
Session: Poster session 19
1354P - Beyond the common mutation: Examining chemotherapy success in uncommon EGFR mutations
Presenter: Chien-Chung Lin
Session: Poster session 19
1355P - Evaluation of the role of variant allele frequency in EGFR mutated non-small cell lung cancer treated with first line osimertinib
Presenter: Marta Brambilla
Session: Poster session 19
1356P - 10-year survivors treated with tyrosine kinase inhibitor for advanced non-small cell lung cancer
Presenter: Yu Tanaka
Session: Poster session 19
1357P - Bevacizumab improved prognosis for advanced EGFR mutant lung adenocarcinoma with brain metastasis receiving cerebral radiotherapy
Presenter: YuanLiang Zhou
Session: Poster session 19
1358P - Safety of tepotinib + EGFR TKI (osimertinib or gefitinib) in patients with EGFRm NSCLC
Presenter: Ernest Nadal
Session: Poster session 19
1359P - Relationship between tumor TP53 gene mutation, circulating anti-p53 antibodies and response to first-line osimertinib in EGFR-mutated NSCLC patients
Presenter: Marc Denis
Session: Poster session 19
1361P - Alectinib for treatment-naïve advanced ALK+ NSCLC selected via blood-based NGS: Updated analyses of outcomes, circulating tumour (ct)DNA and biomarker subgroups from BFAST Cohort A
Presenter: Shirish Gadgeel
Session: Poster session 19
1362P - Association of baseline (BL) anaplastic lymphoma kinase (ALK) fusion detected by circulating tumor DNA (ctDNA) with clinical features and outcomes in the phase III ALTA-3 trial
Presenter: Charu Aggarwal
Session: Poster session 19